Clinical Management of Cavernous Malformations

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Purpose of Review: This study aims to review the current epidemiology and clinical management of patients with cavernous malformations (CM). Recent Findings: Hemorrhage is the most feared complication and leads to morbidity in patients with CM. Multiple studies including three meta-analyses have provided useful estimates of hemorrhage risk, but have failed to identify a modifiable risk factor for prevention of cavernous malformation related hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history. However, accumulating knowledge regarding the roles of CCM 1, 2, and 3 genes has led to the discovery of potential therapeutic targets. Summary: The risk of future hemorrhage in patients with CM is highest in those who have had previously clinical hemorrhages. Estimated risks are helpful in counseling patients and comparing to the risk of surgery. Future clinical trials of candidate medications are likely to target those patients with prior clinical hemorrhage in whom the surgical risk is deemed high.

Original languageEnglish (US)
Article number122
JournalCurrent cardiology reports
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Hemorrhage
Natural History
Meta-Analysis
Counseling
Epidemiology
Clinical Trials
Morbidity
Genes
Therapeutics

Keywords

  • Cavernous angioma
  • Cavernous malformation
  • Epidemiology
  • Management
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical Management of Cavernous Malformations. / Flemming, Kelly.

In: Current cardiology reports, Vol. 19, No. 12, 122, 01.12.2017.

Research output: Contribution to journalReview article

@article{825438e735e0457c8604166a5c239e62,
title = "Clinical Management of Cavernous Malformations",
abstract = "Purpose of Review: This study aims to review the current epidemiology and clinical management of patients with cavernous malformations (CM). Recent Findings: Hemorrhage is the most feared complication and leads to morbidity in patients with CM. Multiple studies including three meta-analyses have provided useful estimates of hemorrhage risk, but have failed to identify a modifiable risk factor for prevention of cavernous malformation related hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history. However, accumulating knowledge regarding the roles of CCM 1, 2, and 3 genes has led to the discovery of potential therapeutic targets. Summary: The risk of future hemorrhage in patients with CM is highest in those who have had previously clinical hemorrhages. Estimated risks are helpful in counseling patients and comparing to the risk of surgery. Future clinical trials of candidate medications are likely to target those patients with prior clinical hemorrhage in whom the surgical risk is deemed high.",
keywords = "Cavernous angioma, Cavernous malformation, Epidemiology, Management, Treatment",
author = "Kelly Flemming",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s11886-017-0931-1",
language = "English (US)",
volume = "19",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - Clinical Management of Cavernous Malformations

AU - Flemming, Kelly

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose of Review: This study aims to review the current epidemiology and clinical management of patients with cavernous malformations (CM). Recent Findings: Hemorrhage is the most feared complication and leads to morbidity in patients with CM. Multiple studies including three meta-analyses have provided useful estimates of hemorrhage risk, but have failed to identify a modifiable risk factor for prevention of cavernous malformation related hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history. However, accumulating knowledge regarding the roles of CCM 1, 2, and 3 genes has led to the discovery of potential therapeutic targets. Summary: The risk of future hemorrhage in patients with CM is highest in those who have had previously clinical hemorrhages. Estimated risks are helpful in counseling patients and comparing to the risk of surgery. Future clinical trials of candidate medications are likely to target those patients with prior clinical hemorrhage in whom the surgical risk is deemed high.

AB - Purpose of Review: This study aims to review the current epidemiology and clinical management of patients with cavernous malformations (CM). Recent Findings: Hemorrhage is the most feared complication and leads to morbidity in patients with CM. Multiple studies including three meta-analyses have provided useful estimates of hemorrhage risk, but have failed to identify a modifiable risk factor for prevention of cavernous malformation related hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history. However, accumulating knowledge regarding the roles of CCM 1, 2, and 3 genes has led to the discovery of potential therapeutic targets. Summary: The risk of future hemorrhage in patients with CM is highest in those who have had previously clinical hemorrhages. Estimated risks are helpful in counseling patients and comparing to the risk of surgery. Future clinical trials of candidate medications are likely to target those patients with prior clinical hemorrhage in whom the surgical risk is deemed high.

KW - Cavernous angioma

KW - Cavernous malformation

KW - Epidemiology

KW - Management

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85031938053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031938053&partnerID=8YFLogxK

U2 - 10.1007/s11886-017-0931-1

DO - 10.1007/s11886-017-0931-1

M3 - Review article

C2 - 29046973

AN - SCOPUS:85031938053

VL - 19

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 12

M1 - 122

ER -